<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">39378126</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>08</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1096-0929</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2024</Year><Month>Oct</Month><Day>08</Day></PubDate></JournalIssue><Title>Toxicological sciences : an official journal of the Society of Toxicology</Title><ISOAbbreviation>Toxicol Sci</ISOAbbreviation></Journal><ArticleTitle>Development and safety of investigational and approved drugs targeting the RAS function regulation in RAS mutant cancers.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">kfae129</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1093/toxsci/kfae129</ELocationID><Abstract><AbstractText>The RAS gene family holds a central position in controlling key cellular activities such as migration, survival, metabolism, and other vital biological processes. The activation of RAS signaling cascades is instrumental in the development of various cancers. Although several RAS inhibitors have gained approval from the United States Food and Drug Administration (FDA) for their substantial antitumor effects, their widespread and severe adverse reactions significantly curtail their practical usage in the clinic. Thus, there exists a pressing need for a comprehensive understanding of these adverse events, ensuring the clinical safety of RAS inhibitors through the establishment of precise management guidelines, suitable intermittent dosing schedules, and innovative combination regimens. This review centers on the evolution of RAS inhibitors in cancer therapy, delving into the common adverse effects associated with these inhibitors, their underlying mechanisms, and the potential strategies for mitigation.</AbstractText><CopyrightInformation>Â© The Author(s) 2024. Published by Oxford University Press on behalf of the Society of Toxicology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Jinjin</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Center for Drug Safety Evaluation and Research of Zhejiang University, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, 310058, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Wentong</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Center for Drug Safety Evaluation and Research of Zhejiang University, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, 310058, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Jiajia</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Center for Drug Safety Evaluation and Research of Zhejiang University, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, 310058, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Zhifei</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Center for Drug Safety Evaluation and Research of Zhejiang University, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, 310058, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Bo</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Institute of Pharmacology &amp; Toxicology, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, 310058, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Medicine, Hangzhou City University, Hangzhou, 310015, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>He</LastName><ForeName>Qiaojun</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Center for Drug Safety Evaluation and Research of Zhejiang University, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, 310058, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Medicine, Hangzhou City University, Hangzhou, 310015, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Innovation Institute for Artificial Intelligence in Medicine of Zhejiang University, Hangzhou, 310018, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Xiaochun</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Center for Drug Safety Evaluation and Research of Zhejiang University, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, 310058, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Innovation Institute for Artificial Intelligence in Medicine of Zhejiang University, Hangzhou, 310018, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Nanhu Brain-computer Interface Institute, Hangzhou, 311100, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hangzhou Institute of Innovative Medicine, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, 310018, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yan</LastName><ForeName>Hao</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Center for Drug Safety Evaluation and Research of Zhejiang University, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, 310058, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Luo</LastName><ForeName>Peihua</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Center for Drug Safety Evaluation and Research of Zhejiang University, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, 310058, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Innovation Institute for Artificial Intelligence in Medicine of Zhejiang University, Hangzhou, 310018, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Toxicol Sci</MedlineTA><NlmUniqueID>9805461</NlmUniqueID><ISSNLinking>1096-0929</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Inhibitors</Keyword><Keyword MajorTopicYN="N">Management</Keyword><Keyword MajorTopicYN="N">Mechanism</Keyword><Keyword MajorTopicYN="N">RAS</Keyword><Keyword MajorTopicYN="N">Toxicity</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>8</Day><Hour>18</Hour><Minute>50</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>8</Day><Hour>18</Hour><Minute>50</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>8</Day><Hour>12</Hour><Minute>22</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39378126</ArticleId><ArticleId IdType="doi">10.1093/toxsci/kfae129</ArticleId><ArticleId IdType="pii">7815736</ArticleId></ArticleIdList></PubmedData></PubmedArticle>